An Assessment of Bone Fluoride and Osteosarcoma

The association between fluoride and risk for osteosarcoma is controversial. The purpose of this study was to determine if bone fluoride levels are higher in individuals with osteosarcoma. Incident cases of osteosarcoma (N = 137) and tumor controls (N = 51) were identified by orthopedic physicians,...

Full description

Saved in:
Bibliographic Details
Published inJournal of dental research Vol. 90; no. 10; pp. 1171 - 1176
Main Authors Kim, F.M., Hayes, C., Williams, P.L., Whitford, G.M., Joshipura, K.J., Hoover, R.N., Douglass, C.W., Gebhardt, M.C., Scarborough, M.T., Gitelis, S., Eckardt, J.J., Neff, J.R., Joyce, M.J., Malawer, M., McGuire, M., Anderson, H.C.
Format Journal Article
LanguageEnglish
Published Los Angeles, CA SAGE Publications 01.10.2011
International Association for Dental Research
Subjects
Online AccessGet full text
ISSN0022-0345
1544-0591
1544-0591
DOI10.1177/0022034511418828

Cover

More Information
Summary:The association between fluoride and risk for osteosarcoma is controversial. The purpose of this study was to determine if bone fluoride levels are higher in individuals with osteosarcoma. Incident cases of osteosarcoma (N = 137) and tumor controls (N = 51) were identified by orthopedic physicians, and segments of tumor-adjacent bone and iliac crest bone were analyzed for fluoride content. Logistic regression adjusted for age and sex and potential confounders of osteosarcoma was used to estimate odds ratios (OR) and 95% confidence intervals (CI). There was no significant difference in bone fluoride levels between cases and controls. The OR adjusted for age, gender, and a history of broken bones was 1.33 (95% CI: 0.56-3.15). No significant association between bone fluoride levels and osteosarcoma risk was detected in our case-control study, based on controls with other tumor diagnoses.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
The National Osteosarcoma Etiology Group, represented by M.C. Gebhardt (Massachusetts General Hospital, Boston, MA, USA), M.T. Scarborough (Shands Medical Center, University of Florida, USA), S. Gitelis (Rush Presbyterian and St. Luke’s Medical Center, USA), J.J. Eckardt (UCLA School of Medicine, USA), J.R. Neff (Nebraska Health System, USA), M.J. Joyce (Cleveland Clinic Foundation, USA), M. Malawer (Washington Cancer Institute, USA), M. McGuire (Creighton University, USA), and H.C. Anderson (University of Kansas Medical Center, USA)
ISSN:0022-0345
1544-0591
1544-0591
DOI:10.1177/0022034511418828